1 Assessing performance and clinical usefulness in prediction models with survival

2 outcomes: practical guidance for Cox proportional hazards models

- 3 David J McLernon,¹ Daniele Giardiello,^{2,3,4} Ben Van Calster,^{3,5} Laure Wynants,⁶ Nan van
- 4 Geloven,³ Maarten van Smeden,⁷ Terry Therneau,⁸ Ewout W Steyerberg³; on behalf of topic
- 5 groups 6 and 8 of the STRATOS Initiative
- ⁶ ¹Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK;
- ⁷ ²Netherlands Cancer Institute, Amsterdam, the Netherlands;
- ⁸ ³Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the
- 9 Netherlands;
- ⁴Institute of Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck,
- 11 Bolzano, Italy;
- ⁵Department of Development and Regeneration, KU Leuven;
- ⁶School for Public Health and Primary Care, Maastricht University;
- ¹⁴ ⁷Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht,
- 15 Utrecht University, Utrecht, the Netherlands;
- ¹⁶ ⁸Department of Quantitative Health Sciences, Mayo Clinic, Rochester MN, USA;
- 17 Corresponding author: David McLernon, Polwarth Building, Institute of Applied Health
- 18 Sciences, University of Aberdeen, Aberdeen, UK, AB25 2ZD; Tel: +441224437152; Email:
- 19 <u>d.mclernon@abdn.ac.uk;</u> Twitter: @davemclernon
- 20 This study was pesented in part at the International Society for Clinical Biostatistics (ISCB)
- 21 42nd Annual Conference, Lyon, July 2021.
- 22 Running Head: Assessing performance in prediction models with survival outcomes
- 23

25 Abstract

Risk prediction models need thorough validation to assess their performance. Validation of models for survival outcomes poses challenges due to the censoring of observations and the varying time horizon at which predictions can be made. We aim to give a description of measures to evaluate predictions and the potential improvement in decision making from survival models based on Cox proportional hazards regression.

As a motivating case study, we consider the prediction of the composite outcome of recurrence and death (the 'event') in breast cancer patients following surgery. We develop a Cox regression model with three predictors as in the Nottingham Prognostic Index in 2982 women (1275 events within 5 years of follow-up) and externally validate this model in 686 women (285 events within 5 years). The improvement in performance was assessed following the addition of circulating progesterone as a prognostic biomarker.

37 The model predictions can be evaluated across the full range of observed follow up times or

for the event occurring by a fixed time horizon of interest. We first discuss recommended

39 statistical measures that evaluate model performance in terms of discrimination, calibration,

40 or overall performance. Further, we evaluate the potential clinical utility of the model to

41 support clinical decision making. SAS and R code is provided to illustrate apparent, internal,

42 and external validation, both for the three predictor model and when adding progesterone.

We recommend the proposed set of performance measures for transparent reporting of thevalidity of predictions from survival models.

Key words: Cox regression model; survival analysis; validation; discrimination; calibration;
 decision analysis; STRATOS Initiative

47

49 Introduction

50 Prediction models for survival outcomes are important for clinicians who wish to estimate a 51 patient's risk (i.e. probability) of experiencing a future outcome. The term 'survival' outcome 52 is used to indicate any prognostic or time-to-event outcome, such as death, progression, or 53 recurrence of disease. Such risk estimates for future events can support shared decision 54 making for interventions in high-risk patients, help manage the expectations of patients, or stratify patients by disease severity for inclusion in trials.¹ For example, a prediction model 55 for persistent pain after breast cancer surgery might be used to identify high risk patients for 56 intervention studies.² 57

Once a prediction model has been developed it is common to first assess its performance for the underlying population. This is referred to as internal validation, which can be performed using the dataset on which the model was developed, for example by cross-validation or bootstrapping techniques.³ External validation refers to performance in a plausibly related population, which requires an independent dataset which may differ in setting, time or place.^{4, 5}

64 Ample guidance exists for assessing the performance of prediction models for binary 65 outcomes, where the logistic regression model is most commonly used for model development.⁶⁻⁸ Validation of a survival model poses more of a challenge due to the 66 67 censoring of observation times when a patient's outcome is undetermined during the study period. If assessing 5-year survival, for instance, some subjects may have less than 5 years 68 of follow-up without experiencing the event of interest.³ Moreover, predictions can be 69 70 evaluated over the entire range of observed follow up times or for the event occurring by a 71 fixed time horizon of interest. The international STRengthening Analytical Thinking for 72 Observational Studies (STRATOS) initiative (http://stratos-initiative.org) began in 2013 and 73 aims to provide accessible and accurate guidance documents for relevant topics in the design and analysis of observational studies.9 74

4

75	This STRATOS article aims to provide guidance for assessing discrimination, calibration,
76	and clinical usefulness for survival models, building on the methodological literature for
77	survival model evaluation. ^{10–12} For illustration, we consider the performance of a Cox model
78	to predict recurrence free survival (i.e. being alive and without breast cancer recurrence) at 5
79	years in breast cancer patients. We also describe how to assess the improvement in
80	predictive ability and decision-making when adding a prognostic biomarker.

82 Methods and Results

In the following, we discuss three key issues for the evaluation of predictions from survival prediction models. We then describe our breast cancer case study, present how we can predict survival outcomes with the Cox proportional hazards model, perform validation of predictions, and assess the potential clinical usefulness of a prediction model.

87 Key issues when validating a survival model

Three major issues differentiate the validation of survival models from models for binary outcomes. First, we need to decide on a time point or time range over which to assess the validation. This choice needs to be grounded in both the available data and the intended practical use of the model predictions. Altman considers a case where a model will be used for individual risk stratification in advanced pancreatic cancer patients.¹³ In such a case a quite short time horizon is indicated of e.g. 18 months. Other situations with longer follow-up might use 3, 5, 10, or even 20 years.

95 A second issue is whether to consider prediction only up to a fixed time point or over an 96 entire range of follow-up. In our case study we focus on 5 years from enrollment as the 97 upper limit. For a cutoff of 5 years, we need to decide if only the binary outcome of whether 98 the event occurred before or after 5 years is of interest, or also the ability to distinguish 99 between survival of 1 and 4 years, for instance. We will give measures of performance for 100 both settings.

101 A last technical issue is that estimation of the baseline survival $S_0(t)$ from the Cox model is 102 necessary for full validation of a prediction model. However, many published reports do not 103 provide this function (see Box 1 for further details).¹⁰

104 Description of the case study

105 We analysed data from patients who had primary surgery for breast cancer between 1978 106 and 1993 in Rotterdam.^{14, 15} Patients were followed until 2007. After exclusions, 2982

6

107 patients were included in the model development cohort (Table 1). The outcome was 108 recurrence-free survival, defined as time from primary surgery to recurrence or death. Over 109 the maximum follow-up time of 19.3 years, 1,713 events occurred, and the estimated median potential follow-up time, calculated using the reverse Kaplan-Meier method, was 9.3 years.¹⁶ 110 111 Out of 2,982 patients, 1,275 suffered a recurrence or death within the follow-up time of 112 interest, which was 5 years, and 126 were censored before 5 years. An external validation 113 cohort consisted of 686 patients with primary node positive breast cancer from the German Breast Cancer Study Group,¹⁷ where 285 suffered a recurrence or died within 5 years of 114 115 follow-up, and 280 were censored before 5 years. Five year predictions were chosen as that 116 was the lowest median survival from the two cohorts (Rotterdam cohort, 6.7 years; German 117 cohort, 4.9 years).

118 **Prediction of survival outcomes**

The Cox proportional hazards model is a standard for analysing survival data in biomedical settings¹⁸ A Cox model estimates log hazard ratios, but for prediction, estimation of the baseline survival is also required. Both are needed for a full assessment of performance of a survival model in new patients (external validation, Box 1).

123 Model development in the case study

124 A Cox regression model was fit to estimate recurrence free survival using three predictors: 125 number of lymph nodes (0, 1-3, >3), tumour size (≤ 20 mm, 21-50 mm, >50 mm) and 126 pathological grade (1, 2, 3, see Table 2). Although we emphasize that it is generally poor 127 practice to categorise continuous variables, tumour size was not available in continuous form 128 in the dataset, and number of lymph nodes was categorised to match its form in the wellknown Nottingham Prognostic Index.¹⁹²⁰ Since we were interested in predictons up to 5 129 130 years, we applied administrative censoring at 5 years. The Cox model assumes that hazards 131 for different values of a predictor are proportional during follow-up. While found some 132 evidence of non-proportional hazards (p<0.001, Grambsch and Therneau global test), we

7

- 133 chose to ignore this violation here since it was relatively minor at graphical inspection.
- 134 Furthermore, predictions made at the time of administrative censoring (5 years here) have
- 135 been shown to be robust regardless of such violations.²¹
- 136 The formula for the prognostic index was estimated as follows:

$$PI = 0.383 \times 1(if \ size \ is \ 21 - 50mm) + 0.664 \times 1(if \ size \ is \ > 50) + 0.360$$

$$\times 1(if \ 1 \ to \ 3 \ nodes) + 1.063 \times 1(if \ nodes > 3) + 0.375 \times 1(if \ grade = 3)$$

137 The probability of experiencing the event within 5 years can be calculated as:

138
$$1-S(5) = 1 - S_0(5)^{\exp(PI)} = 1 - 0.802^{\exp(PI)}$$

139

140 The baseline survival at 5 years (0.802) applies to the reference categories for the three 141 predictors in the model (see R and SAS code in 142 https://github.com/danielegiardiello/Prediction_performance_survival). So, a woman with a tumor size <=20mm, no nodes, and grade<3, has an estimated risk of $1 - 0.802^{1} = 19.8\%$ of 143 144 recurrence or breast cancer mortality within 5 years.

145

146 *Measures of performance*

Model performance was assessed in the development dataset (apparent validation) and in the German dataset (external validation). Internal validation was assessed using the bootstrap resampling approach which provides stable estimates of performance for the population where the sample originated from. The difference between the apparent performance and the internal performance represents the "optimism" in performance of the original model (see Appendix 1 for further details).

153 Discrimination

8

A first question is how well the model predictions separate high from low risk patients: discriminative ability. Patients with an earlier event time should exhibit a higher risk and those with later event time a lower risk.

157 Fixed time point discrimination

Measures that assess the prediction by a fixed time point are the similar to those for binomial outcomes. A primary issue that arises, however, is censoring in the validation data set. If we choose an evaluation time of 5 years, for instance, how are subjects who are censored before 5 years in the validation set to be assessed? For these we have a predicted risk at 5 years from the model, but do not have an observed value of the outcome at 5 years. One approach is to use inverse probability of censoring weights (IPCW), to reassign the case weights of those censored to other observations with longer follow up (see Table S1).

165 Uno applies such inverse weights, and this is our recommended method for assessing discrimination at a fixed time point, though many others exist.^{22, 23} It assesses all pairs of 166 167 patients where one experiences the event before the chosen time point and the other 168 remains event free up to that time and calculates the proportion of those pairs for which the 169 first mentioned patient has highest estimated risk (Table S2). Uno's IPCW approach for 5 170 year prediction was 0.71 [95% CI 0.69 to 0.73] at model development (apparent validation). 171 Internal validation suggested no statistical optimism (remained 0.71 using 500 bootstrap 172 samples), while external validation showed a slightly poorer performance (0.69 [95% CI 0.63 173 to 0.75], Table 3).

174 Time range discrimination

Harrell's concordance index (C) is commonly used to assess global performance.²⁴ It is calculated as a fraction where the denominator is the number of all possible pairs of patients in which one patient experiences the event first and the other later. Harrell's C quantifies the degree of concordance as the proportion of such pairs where the patient with a longer survival time has better predicted survival (lower PI). Using our time range of 0 to 5 years,

9

Harrell's C was 0.67 [95% CI 0.66 to 0.69] at apparent validation. Again, no optimism was noted (C=0.67) and a slightly lower performance at external validation (C=0.65 [95% CI 0.62 to 0.69]). Uno's C uses a time dependent weighting that more fully adjusts for censoring (more details in appendix 2).²⁵ Uno's C was also 0.67 [95% CI 0.66 to 0.69] at apparent validation, 0.67 at internal validation and 0.64 [95% CI 0.60 to 0.68] for external validation in our case study.

186 Calibration

A second important question to answer when validating a model is 'how well do observed outcomes agree with model predictions? This relates to calibration.^{8, 11} Assessment of calibration is essential at external validation ^{3, 26}. Below we describe a hierarchy of calibration levels and its application to survival model predictions, in line with a previously proposed framework.⁸

192 Mean calibration

Mean calibration (or calibration-in-the-large) refers to agreement of the predicted andobserved survival fraction.

Fixed time point mean calibration is typically expressed in terms of the ratio of the observed survival fraction and the average predicted risk. The observed survival fraction at the chosen time point needs to be estimated due to censoring, which can be done using the Kaplan-Meier estimator. For the external validation cohort, the Kaplan-Meier estimate of experiencing the event within 5 years was 51%, while the average predicted probability was 49%. This indicates a minor deviation from perfect mean calibration (a ratio of 1.04, 95% CI [0.95 to 1.14], Table 3).

202 Weak calibration

The term 'weak' refers to the limited flexibility in assessing calibration. We are essentially summarising calibration of the observed proportions of outcomes versus predicted

10

probabilities using only two parameters i.e. a straight line. In other words, perfect weak calibration is defined as mean calibration ratio and calibration slope of unity. Mean calibration indicates systematic underprediction or overprediction. The calibration slope indicates the overall strength of the PI, which can be interpreted as the level of overfitting (slope <1) or underfitting (slope>1).

For a fixed time point assessment of weak calibration, we can predict the outcome at 5 years for every patient but we need to determine the observed outcome at 5 years even for those who were censored before that time. One way to do this is to fit a new 'secondary' Cox model using all of the validation data with the PI from the development model as the only covariate. The calibration slope is the coefficient of the PI. In our case study it was 1.07 [95% CI 0.82 to 1.32] for the 5 year predictions, confirming very good calibration.

216 Moderate calibration

Moderate calibration concerns whether among patients with the same predicted risk, the observed event rate equals the predicted risk.⁶ A smooth calibration curve of the observed event rates against the predicted risks is used for assessment of moderate calibration.

The relation between the outcome at a fixed time point and predictions can be visualised by plotting the predicted risk from another 'secondary' Cox model against the predicted risk from the development model.²⁷ The details are presented in Appendix 3 and Table S1.

223 The calibration plot shows good agreement between predictions from the developed model 224 and observed event rates as estimated by the secondary model (Fig 1A). This plot can be 225 characterized further by some calibration metrics. The Integrated Calibration Index (ICI) is 226 the mean absolute difference between smoothed observed proportions and predicted 227 probabilities. The E50 and E90 denote the median and the 90th percentile absolute difference between observed and predicted probabilities of the outcome.²⁷ For our validation 228 229 cohort, we estimated ICI was 0.03 [95% CI 0.01 to 0.07], E50=0.03 [95% CI 0.007 to 0.07] 230 and E90=0.06 [95% CI 0.02 to 0.14].

11

231 Strong calibration

Ideally, we would check for strong calibration by comparing predictions to the observed
event rate for every covariate pattern observed in the validation data. However, this is hardly
ever possible due to limited sample size and/or the presence of continuous predictors.

235 Time range calibration

236 Mean calibration can be assessed by comparing observed to predicted event counts, a 237 method that is closely related to the standardized mortality ratio (SMR), common in epidemiology.^{28, 29} For the validation cohort, the total number of observed recurrent free 238 239 survival endpoints was 285 versus an expected number of 269.9 (ratio 1.06 [0.94 to 1.19]). 240 This agrees with the 5 year fixed time results. For weak and moderate calibration 241 assessment, a similar path to the fixed time approach can be followed using a Poisson 242 model with the predicted cumulative hazard from the original Cox model as an offset.¹¹ The 243 weak calibration results gave a calibration slope of 1.05 [95% CI 0.80 to 1.30] respectively, 244 again confirming very good calibration. Computational details are in Appendix 3.

245

246 Overall performance

Another common measure used at validation of predictions up to a fixed time point, encompassing both discrimination and calibration, is the Brier score.^{30–32} This measure also involves inverse weights and is the mean squared difference between observed survival at a fixed time point (event =1 or 0) and the predicted risk by that time point.

The Brier score for a model can range from 0 for a perfect model to 0.25 for a noninformative model in a dataset with a 50% event rate by the fixed time point. When the event rate is lower, the maximum score for a non-informative model is lower, which complicates interpretation. A solution is to scale the Brier score, B, at 0 - 100% by calculating a scaled

12

Brier score as 1-B/B₀, where B₀ is the Brier score when using the same estimated risk (the overall Kaplan-Meier estimate) for all patients.³³

At apparent validation, the Brier score was 0.210 [95% Cl 0.204 to 0.216], with a null model Brier score B_0 of 0.245, so a scaled Brier score of 14.3% [95% Cl 11.8% to 16.8%]. The internal validation results were very similar to the apparent validation. At external validation, the Brier score was slightly higher at 0.224 [95% Cl 0.210 to 0.240] and the scaled Brier score lower at 10.2% [95% Cl 4.0% to 15.9%] (Table 3).

262

263 Approaches to assess clinical usefulness

264 Measures of discrimination and calibration quantify a model's predictive ability from a 265 statistical perspective. However, they fall short with regard to evaluating whether the model may actually improve clinical decision making.³⁴⁻³⁶ Specifically, we may wish to determine 266 267 whether a model is useful to support targeting of an additional treatment to high risk patients. This is what decision curve analysis aims to do by calculating the Net Benefit of a model.^{36, 37} 268 269 First, we need to define a clinically motivated risk threshold to decide who should be treated. 270 For example, we may offer chemotherapy to patients with a 5-year risk of recurrence or 271 death exceeding 20%. Using this 20% threshold, treatment benefit is obtained for patients 272 who would die or whose cancer would recur within 5-years and have a risk ≥20%: true 273 positive classifications. Harm of unnecessary treatment is caused to those patients who 274 would not die or whose cancer would not recur within 5-years but have a risk ≥20%: false-275 positive classifications. ³⁸If the harm of unnecessary treatment (i.e. a false positive decision) 276 is small then a risk threshold close to 0% is sensible, as it would lead to treating most 277 patients. However, if overtreatment is harmful, such as major surgery, then a higher risk 278 threshold may be apt. The odds of the risk threshold equals the harm-to-benefit ratio. 279 Realizing this, we can now calculate the Net Benefit by calculating the proportion of true

13

280 positives (that benefit) and substracting from that the proportion of false positives (that are

281 harmed), weighted by the harm-to-benefit ratio (w):³⁸

Net Benefit =
$$\frac{(TP - w * FP)}{N}$$

where *TP* is the number of true-positive decisions, *FP* the number of false-positive decisions, *N* is the total number of patients and *w* is the odds of the threshold. When we are dealing with survival data, the Net Benefit can be calculated in the presence of censoring at any prediction horizon (Vickers et al. 2008).³⁵ For survival data *TP* and *FP* are calculated as:

$$TP(t) = [1 - S(t, X = 1)] * P(X = 1) * N$$

$$FP(t) = [S(t, X = 1)] * P(X = 1) * N$$

$$w(t) = \frac{P_t}{1 - P_t}$$

where P_t is the predicted probability at time t, 1 - S(t, X=1) the observed event probability for those classified as positive, and P(X=1) is the probability of a positive classification.

288 Considering only one single risk threshold for evaluation of Net Benefit is usually too limited, 289 since the perceived harms and benefits of treatment may differ between decision makers 290 and be context-dependent. Hence, we specify a range of reasonable thresholds which would 291 be acceptable for treatment decisions.³⁹ The Net Benefit can be visualised for this range of 292 clinically relevant thresholds using a decision curve. Decision curve analysis allows us to 293 compare the Net Benefit for different prediction models to the default strategies of treating all 294 or no patients ('treat all' and 'treat none').^{37, 40 7}

Based on previous research we focused on a range of thresholds from 14% to 23% for adjuvant chemotherapy (Figure 1B).⁴¹ If we choose the threshold of 23% the model has a Net Benefit of 0.27. This means that the model would identify 27 patients per 100 who will have recurrent breast cancer or die within 5 years of surgery and thus require adjuvant

14

chemotherapy. The decision curve based on the development data shows that the model Net Benefit is only marginally greater than a 'treat all' reference strategy at the highest threshold within the acceptable range of 23%. However, in the external validation dataset, the model is not useful as it has similar Net Benefit values to the 'treat all' strategy for the full range of clinically acceptable thresholds. Therefore it is unlikely that the model is useful to support decisions around adjuvant chemotherapy (Fig 1C).

All the methods we have described are summarised in the Appendix (Table S2).

306 Model extension with a marker

307 We recognize that a key interest in contemporary medical research is whether a particular 308 marker (e.g. molecular, genetic, imaging) adds to the performance of an existing prediction 309 model. Validation in an independent dataset is the best way to compare the performance of 310 a model with and without a new marker. We extended our model by adding the progesterone 311 (PGR) biomarker at primary surgery to the Cox model (Table 2). The results are described in 312 appendix 4 and presented in Table 3. Briefly, at external validation the improvement in fixed 313 time point discrimination was from 0.693 to 0.722 (delta AUC of 0.029), the improvement in 314 time range discrimination was from 0.639 to 0.665 (delta C of 0.026). There was an 315 improvement in net benefit (0.367 versus 0.362), which means we need to measure PGR in 316 200 patients for one additional net true positive classification.

317 Software

- All analyses were done in SAS v 9.4 (SAS Institute Inc., Cary, NC, USA) and R version 319 3.6.3, R Foundation for Statistical Computing, Vienna, Austria). Code is provided at 320 https://github.com/danielegiardiello/Prediction_performance_survival.
- 321

322 Discussion

15

323 This article provides guidance for different measures that may be used to assess the 324 performance of a Cox proportional hazards model. The performance measures were 325 illustrated for use at model development and external validation. At model development, the 326 apparent performance can directly be assessed for a prediction model, and internal validity 327 is commonly assessed by cross-validation or bootstrapping techniques. External validation is 328 considered a stronger test for a model. We first illustrated how to evaluate the quality of 329 predictions using measures of discrimination, calibration and overall performance. We then 330 showed how to evaluate the quality of decisions according to Net Benefit and decision curve 331 analysis. Finally, we illustrated that the performance measures are also applicable when 332 assessing the added value of a new predictor, where specific interest may be in 333 improvement in discrimination and Net Benefit.

334 We made a distinction between measures that can be used to assess the performance of 335 predictions for specific time points (e.g. 5- or 10-year survival) and over a range of follow up 336 time. Prediction at specific timepoints will often be most relevant since clinicians and patients 337 are usually interested in prognosis within a specified period of time. As described, AUC, 338 smooth calibration curves and Brier score focus on such specific time points. Of note, 339 estimation of the baseline survival is treated as an optional extra step in most statistical 340 software packages. The consequence is that such key information is not available for most 341 prediction models that are based on the Cox model. This may lead to the misconception that 342 the Cox model does not give estimates of absolute risk. If the baseline survival for specific 343 times points is given together with the estimated log hazard ratios, external validation is 344 feasible (see Table S3). The discrimination and Brier score methods presented here can 345 easily be applied to parametric survival models such as Weibull or more flexible approaches⁴² 346

In the breast cancer study, the optimism in all performance measures was minimal at internal validation. This reflects the relatively large sample size in relation to the small number of predictors, which allows for robust statistical modeling. The performance at

16

external validation was slightly poorer, as can in general be expected and may reflect slightly
 differential prognostic effects, but also differences in case-mix and censoring distribution.⁴³
 We have not addressed the common problem of missing values for predictors, which needs
 somewhat more complex handling than for binary outcome prediction.⁴⁴

354 Dealing with censoring is a key challenge in the assessment of performance of a prediction 355 model for survival outcomes. If censoring is merely by end of study period ('administrative 356 censoring'), the assumption of censoring being non-informative may be reasonable. This 357 may not be the case for patients who are lost to follow-up, where censoring may depend on 358 predictors in the model and other characteristics. As well as the IPCW and secondary 359 modelling approaches presented here, other approaches are possible, for example using 360 pseudo-observations, which often makes the assumption of fully uninformative censoring. 361 Extensions that can deal with covariate-dependent censoring have been proposed.^{45, 46}

362 **Recommendations**

We provide some recommendations for assessing the performance of a survival prediction models (Box 2 and Table S3). For calibration at external validation, we recommend plotting a smooth calibration curve (moderate calibration) and reporting both mean and weak calibration. Where no baseline survival is reported from the development study, only crude visual calibration and discrimination assessment may be possible (Appendix 5). Moreover, we recommend that researchers developing or validating a prognostic model follow the TRIPOD checklist to ensure transparent reporting.⁷

Net Benefit, with visualisation in a decision curve, is a simple summary measure to quantify the potential clinical usefulness when a prediction model intends to support clinical decisionmaking. Discrimination and calibration are important but not sufficient for clinical usefulness. For example, the decision threshold for clinical decisions may be outside the range of predictions provided by a model, even if that model has a high discriminatory ability.

17

Furthermore, poor calibration can ruin Net Benefit, such that using a model can lead to worse decisions than without a model.⁴⁷

We recognize that other performance measures are available that have not been described in this paper, which may be important under specific circumstances. We recommend that future work should focus on assessing performance for various extensions of predicting survival, such as for competing risk and dynamic prediction situations.^{22, 48–51}

In conclusion, the provided guidance in this paper may be important for applied researchers to know how to assess, report, and interpret discrimination, calibration and overall performance for survival prediction models. Decision curve analysis and Net Benefit provide valuable additional insight on the usefulness of such models. In line with the TRIPOD recommendations, these measures should be reported if the model is to be used to support clinical decision making.

388 References

- Hemingway H, Croft P, Perel P, et al: Prognosis research strategy (PROGRESS) 1: A framework for
 researching clinical outcomes. BMJ (Online) 346, 2013
- 391 2. Meretoja TJ, Andersen KG, Bruce J, et al: Clinical prediction model and tool for assessing risk of
 392 persistent pain after breast cancer surgery. Journal of Clinical Oncology 35:1660–1667, 2017
- **3**. Steyerberg EW, Harrell FE: Prediction models need appropriate internal, internal–external, and
- external validation. Journal of Clinical Epidemiology 69:245–247, 2016
- 4. Altman DG, Royston P: What do we mean by validating a prognostic model? Statistics in Medicine
 19:453-473, 2000
- 397 5. Justice AC, Covinsky KE, Berlin JA: Assessing the generalizability of prognostic information. Annals
 398 of Internal Medicine 130:515–524, 1999
- 399 6. Steyerberg EW, Vickers AJ, Cook NR, et al: Assessing the performance of prediction models: A
- 400 framework for traditional and novel measures. Epidemiology 21:128–138, 2010
- 401 **7**. Collins GS, Reitsma JB, Altman DG, et al: Transparent reporting of a multivariable prediction model
- for individual prognosis or diagnosis (TRIPOD): The tripod statement. Journal of Clinical Epidemiology
 68:112-121, 2015
- 404 8. van Calster B, Nieboer D, Vergouwe Y, et al: A calibration hierarchy for risk models was defined:
 405 From utopia to empirical data. Journal of Clinical Epidemiology 74:167–176, 2016
- 406 **9**. Sauerbrei W, Abrahamowicz M, Altman DG, et al: STRengthening analytical thinking for
- 407 observational studies: the STRATOS initiative [Internet]. Statistics in medicine 33:5413–5432,
- 408 2014[cited 2021 Dec 21] Available from: https://pubmed.ncbi.nlm.nih.gov/25074480/
- 409 10. Royston P, Altman DG: External validation of a Cox prognostic model: principles and methods.
 410 Medical Research Methodology 13:33, 2013
- 411 **11**. Crowson CS, Atkinson EJ, Therneau TM, et al: Assessing calibration of prognostic risk scores.
 412 Statistical Methods in Medical Research 25:1692–1706, 2016
- 413 **12**. Rahman MS, Ambler G, Choodari-Oskooei B, et al: Review and evaluation of performance
- 414 measures for survival prediction models in external validation settings. BMC Medical Research
 415 Methodology 17, 2017
- 416 **13**. Stocken DD, Hassan AB, Altman DG, et al: Modelling prognostic factors in advanced pancreatic
 417 cancer. British Journal of Cancer 99, 2008
- 418 **14**. Foekens JA, Peters HA, Look MP, et al: The Urokinase System of Plasminogen Activation and
 419 Prognosis in 2780 Breast Cancer Patients 1. Cancer Research 60:636–643, 2000
- 420 **15**. Sauerbrei W, Royston P, Look M: A new proposal for multivariable modelling of time-varying
- 421 effects in survival data based on fractional polynomial time-transformation. Biometrical Journal
- 422 49:453–473, 2007

- 423 **16**. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Controlled
 424 Clinical Trials 17:343–346, 1996
- 425 **17**. Schumacher M, Bastert G, Bojar H, et al: Randomized 2 x 2 trial evaluating hormonal treatment
- 426 and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer
- 427 Study Group. Journal of Clinical Oncology 12:2086–2093, 1994
- **18**. Mallett S, Royston P, Dutton S, et al: Reporting methods in studies developing prognostic models
 in cancer: a review. BMC Medicine 8, 2010
- 430 **19**. Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors in multiple regression:
- 431 a bad idea [Internet]. Statistics in Medicine 25:127–141, 2006[cited 2021 Dec 22] Available from:
- 432 https://onlinelibrary.wiley.com/doi/full/10.1002/sim.2331
- 433 20. Haybittle JL, Blamey RW, Elston CW, et al: A PROGNOSTIC INDEX IN PRIMARY BREAST CANCER. Br
 434 J Cancer 45:361–366, 1982
- 435 **21**. van Houwelingen HC: From model building to validation and back: a plea for robustness.
- 436 Statistics in Medicine 33, 2014
- 437 **22**. Blanche P, Dartigues JF, Jacqmin-Gadda H: Review and comparison of ROC curve estimators for a
- time-dependent outcome with marker-dependent censoring. Biometrical Journal 55:687–704, 2013
- 439 23. Uno H, Cai T, Tian L, et al: Evaluating prediction rules for t-year survivors with censored
- regression models. Journal of the American Statistical Association 102:527–537, 2007
- 441 **24**. Harrell FE, Lee KL, Califf RM, et al: Regression modelling strategies for improved prognostic
 442 prediction. Statistics in Medicine 3:143–152, 1984
- 443 **25**. Uno H, Cai T, Pencina MJ, et al: On the C-statistics for evaluating overall adequacy of risk
- 444 prediction procedures with censored survival data. Statistics in Medicine 30:1105–1117, 2011
- 445 **26**. van Calster B, McLernon DJ, van Smeden M, et al: Calibration: The Achilles heel of predictive
 446 analytics. BMC Medicine 17, 2019
- 447 **27**. Austin PC, Harrell FE, van Klaveren D: Graphical calibration curves and the integrated calibration
- 448 index (ICI) for survival models. Statistics in Medicine 39:2714–2742, 2020
- **28**. Breslow N, Day N: Statistical Methods in Cancer Research. Lyon, International Agency for
 Research on Cancer, 1987
- 451 **29**. Breslow NE, Lubin JH, Marek P, et al: Multiplicative Models and Cohort Analysis. Journal of the
 452 American Statistical Association 78:1–12, 1983
- 453 **30**. Graf E, Schmoor C, Sauerbrei W, et al: Assessment and comparison of prognostic classification
 454 schemes for survival data. Statistics in Medicine 18:2529–2545, 1999
- 455 **31**. Gerds TA, Schumacher M: Consistent estimation of the expected brier score in general survival
 456 models with right-censored event times. Biometrical Journal 48:1029–1040, 2006

- 457 **32**. Blattenberger G, Lad F: Separating the Brier Score into Calibration and Refinement Components:
- 458 A Graphical Exposition. The American Statistician 39:26–32, 1985
- 459 **33**. Kattan MW, Gerds TA: The index of prediction accuracy: an intuitive measure useful for
- 460 evaluating risk prediction models. Diagnostic and Prognostic Research 2, 2018
- 461 **34**. van Calster B, Wynants L, Verbeek JFM, et al: Reporting and Interpreting Decision Curve Analysis:
- A Guide for Investigators. European Urology 74:796–804, 2018
- 463 **35**. Vickers AJ, Cronin AM, Elkin EB, et al: Extensions to decision curve analysis, a novel method for
- 464 evaluating diagnostic tests, prediction models and molecular markers. BMC Medical Informatics and
 465 Decision Making 8, 2008
- **36**. Vickers AJ, Elkin EB: Decision Curve Analysis: A Novel Method for Evaluating Prediction Models.
- 467 Medical Decision Making 26:565–574, 2006
- 468 **37**. Kerr KF, Brown MD, Zhu K, et al: Assessing the clinical impact of risk prediction models with
- decision curves: Guidance for correct interpretation and appropriate use. Journal of Clinical
- 470 Oncology 34:2534–2540, 2016
- 471 **38**. Peirce C: The numerical measure of success of predictions. Science 4:453–454, 1884
- 472 **39**. Vickers AJ, van Calster B, Steyerberg EW: Net benefit approaches to the evaluation of prediction
- 473 models, molecular markers, and diagnostic tests. BMJ (Online) 352, 2016
- 474 40. Vickers AJ, van Calster B, Steyerberg EW: A simple, step-by-step guide to interpreting decision
 475 curve analysis. Diagnostic and Prognostic Research 3, 2019
- 476 **41**. Karapanagiotis S, Pharoah PDP, Jackson CH, et al: Development and external validation of
- 477 prediction models for 10-year survival of invasive breast cancer. Comparison with predict and
- 478 cancermath. Clinical Cancer Research 24:2110–2115, 2018
- 479 **42**. Ng R, Kornas K, Sutradhar R, et al: The current application of the Royston-Parmar model for
- 480 prognostic modeling in health research: a scoping review [Internet]. Diagnostic and Prognostic
- 481 Research 2018 2:1 2:1–15, 2018[cited 2021 Dec 21] Available from:
- 482 https://diagnprognres.biomedcentral.com/articles/10.1186/s41512-018-0026-5
- 483 43. van Klaveren D, Gönen M, Steyerberg EW, et al: A new concordance measure for risk prediction
 484 models in external validation settings. Statistics in Medicine 35:4136–4152, 2016
- 485 **44**. Keogh RH, Morris TP: Multiple imputation in Cox regression when there are time-varying effects
- 486 of covariates. Statistics in Medicine 37:3661–3678, 2018
- 487 **45**. Overgaard M, Parner ET, Pedersen J: Pseudo-observations under covariate-dependent censoring.
- 488 Journal of Statistical Planning and Inference 202:112–122, 2019
- 489 **46**. Binder N, Gerds TA, Andersen PK: Pseudo-observations for competing risks with covariate
- 490 dependent censoring. Lifetime Data Analysis 2013 20:2 20:303-315, 2013

491 492	47 . van Calster B, Vickers AJ: Calibration of Risk Prediction Models. Medical Decision Making 35:162–169, 2015
493 494 495	48 . Bansal A, Heagerty PJ: A comparison of landmark methods and time-dependent ROC methods to evaluate the time-varying performance of prognostic markers for survival outcomes. Diagnostic and Prognostic Research 3, 2019
496 497	49 . Schoop R, Beyersmann J, Schumacher M, et al: Quantifying the predictive accuracy of time-to- event models in the presence of competing risks. Biometrical Journal 53:88–112, 2011
498 499 500	50. Rizopoulos D, Molenberghs G, Lesaffre EMEH: Dynamic predictions with time-dependent covariates in survival analysis using joint modeling and landmarking. Biometrical Journal 59:1261–1276, 2017
501 502	51 . Wolbers M, Koller MT, Witteman JCM, et al: Prognostic Models With Competing Risks. Epidemiology 20:555–561, 2009
503	
504	
505	
506	
507	
508	
509	
510	
511	
512	
513	
514	
515	

22

516 Figure legends

- 517 Figure 1 Calibration plot of model predicting recurrence within 5 years for patients with
- 518 primary breast cancer in external validation data for A) Fixed time assessment. Decision
- 519 curves for predicted probabilities without (green line) and with (blue line) PGR in B)
- 520 development dataset; C) external validation dataset.

521

- 522 A External validation: Fixed time assessment (predicted risk at 5 years from original model
- 523 versus secondary model)
- 524 B Decision curve analysis in development data
- 525 C Decision curve analysis in external validation data

526

- 527 Footnote: In part A, the solid red line represents a restricted cubic spline between the
- 528 predicted risk from the developed model and the predicted risk from the refitted Cox model
- at 5 years. The dashed lines represent the 95% confidence limits of the predicted risks from
- the refitted model. At the bottom of the plots is the density function for the predicted risk from
- 531 the developed model.

532

- 533 534
- . .
- 535 536
- 537
- 538
- 539
- 540
- 541

542

Hazard ratios express how baseline patient characteristics (or predictors) are associated with the hazard rate, that is the instantaneous rate of the event occurring at time t, having survived until time t. Mathematically, the Cox model for the hazard rate, h(t), is

$$h(t) = h_0(t) \exp(\beta_1 x_1 + \beta_2 x_2 + \beta_3 x_3 + \dots + \beta_p x_p) = h_0(t) \exp(\text{PI}),$$

where the β 's are regression coefficients for the *p* predictors x_1 to x_p (e.g., the patient's age, disease stage, comorbidity). These regression coefficients are the log of the hazard ratios. The prognostic index, PI, represents the sum of the regression coefficients multiplied by the value of their respective predictors. The Cox model assumes that hazards for different values of a predictor are proportional during follow-up. For example, if the hazard of the event for patient A is half that of patient B at time *t*, the hazard ratio of 0.5 holds for these two patients at any other time point.

The baseline hazard function $h_0(t)$ is the same for all patients analogous to the intercept in linear or logistic regression models. If the primary focus of an analysis is relative risk estimation, the Cox model can be used to obtain hazard ratios without worrying about baseline hazard estimation. For estimating the risk that a patient experiences the event, i.e. absolute risk estimation, we require the baseline survival function $S_0(t)$ which is the predicted risk of survival for the patient whose predictor values are the reference categories (for categorical predictors) or zero/the mean (for continuous predictors). By integrating the hazard function from time 0 to *t* we obtain the cumulative hazard function, $H(t) = H_0(t)\exp(PI)$, where $H_0(t)$ is the baseline cumulative hazard function. $H_0(t)$ is then used to estimate the probability of survival up to time *t*, i.e. not experiencing the event up to time t:

$$S(t) = S_0(t)^{\exp(\beta_1 x_1 + \beta_2 x_2 + \beta_3 x_3 + \dots + \beta_p x_p)} = S_0(t)^{\exp(\text{PI})}$$

where $S_0(t) = \exp(-H_0(t))$, the baseline survival at time *t* (e.g., *t* = 5 years after surgery). The absolute risk of an event within *t* years is calculated as 1 - S(t). The baseline hazard of a Cox model is often estimated non-parametrically in contrast to parametric survival models such as the accelerated failure time model.

Estimates of absolute risk are necessary for many of the performance measures discussed below. A model development study hence needs to have reported the baseline hazard function or baseline survival function, or at least survival at the time point of interest, and a specification of calculation of the PI. This is analogous to a logistic regression model to predict a binary outcome, which additionally needs reporting of a model intercept rather than only odds ratios.

Table 1 Characteristics of the breast cancer cohorts used for model development and

external validation^{14, 17}

Characteristic		Development cohort	Validation cohort	
		(n=2982, 1275	(n=686, 285 events	
		events <5 years)	<5 years)	
Size (mm)	≤20	1387 (46.5)	180 (26.2)	
	21-50	1291 (43.3)	453 (66.0)	
	>50	304 (10.2)	53 (7.7)	
Number of Nodes	0	1436 (48.2)	0 (0.0)	
	1 to 3	764 (25.6)	376 (54.8)	
	>3	782 (26.2)	310 (45.2)	
Grade of Tumour	1 or 2	794 (26.6)	525 (76.5)	
	3	2188 (73.4)	161 (23.5)	
Age (years: median (IQR))		54 (45 to 65)	53 (46 to 61)	
Circulating progesterone (F	PGR,	41 (4 to 198)	33 (7 to 132)	
ng/mL: median (IQR))				

547 Numbers (%) unless otherwise stated

25

Table 2 Cox regression models predicting event free survival in Rotterdam breast
cancer development dataset (n=2982), without and with PGR

	Without PGR	With PGR
	Hazard ratio	Hazard ratio
	(95% CI)	(95% CI)
Size (mm)		
≤20	1	1
21-50	1.47 (1.29 to 1.67)	1.44 (1.26 to 1.63)
>50	1.94 (1.62 to 2.32)	1.90 (1.59 to 2.27)
Number of nodes		
0	1	1
1 to 3	1.43 (1.24 to 1.66)	1.46 (1.26 to 1.70)
>3	2.89 (2.52 to 3.32)	2.88 (2.51 to 3.31)
Tumour grade		
1 or 2	1	1
3	1.46 (1.27 to 1.67)	1.37 (1.19 to 1.58)
PGR (ng/ml)		1.46 [§] (1.27 to 1.68)
PGR1 [§]		1.40 (1.27 (0 1.00)

For model without PGR, the formula for the prognostic index is:

 $PI = 0.383 \times 1(if \ size \ is \ 21 - 50mm) + 0.664 \times 1(if \ size \ is \ > 50) + 0.360$

 $\times 1(if \ 1 \ to \ 3 \ nodes) + 1.063 \times 1(if \ nodes > 3) + 0.375 \times 1(if \ grade = 3)$

The survival at 5 years can be calculated as:

 $S(5) = 0.802^{\exp(PI)}$

For model with PGR:

 $\begin{aligned} PI &= 0.362 \times 1(if \ size \ is \ 21 - 50mm) + 0.641 \times 1(if \ size \ is \ > 50) + 0.381 \\ &\times 1(if \ 1 \ to \ 3 \ nodes) + 1.059 \times 1(if \ nodes \ > 3) + 0.317 \times 1(if \ grade = 3) \\ &- 0.003 \times PGR + 0.013 \times PGR1 \end{aligned}$

where $PGR1 = max\left(\frac{PGR}{61.81}, 0\right)^3 + \frac{\left(41 \times max\left(\frac{(PGR-4.86)}{61.81}, 0\right)^3 - 486 \times max\left(\frac{(PGR-4.1)}{61.81}, 0\right)^3\right)}{445}$

The survival at 5 years can be calculated as:

 $S(5) = 0.759^{\exp(PI)}$

[§]Since PGR was fitted as a restricted cubic spline function, it is presented as an interquartile HR to aid interpretation i.e. the hazard of mortality for the 25th percentile value (i.e. PGR=4 ng/ml) versus the hazard of mortality for the 75th percentile value (198 ng/ml).

Table 3 Performance of breast cancer model with and without PGR at 5 years in development (n=2982) and validation data (n=686)

Performance measure	Internal Validation: apparent performance		Internal Validation: performance with		External Validation	
		optimism correction by bootstrap				
			resar	npling		
	Without PGR	With PGR	Without	With	Without PGR	With PGR
			PGR	PGR		
Discrimination						
Time range						
Harrell's C (SE)	0.674 (0.660 to 0.688)	0.682 (0.668 to 0.696)	0.673	0.680	0.652 (0.619 to 0.685)	0.679 (0.648 to 0.710)
Uno's C (SE)	0.673 (0.657 to 0.689)	0.682 (0.666 to 0.698)	0.672	0.680	0.639 (0.602 to 0.676)	0.665 (0.628 to 0.702)
Fixed time						
Uno's IPCW (5 yrs)	0.712 (0.693 to 0.732)	0.720 (0.701 to 0.740)	0.710	0.717	0.693 (0.633 to 0.753)	0.722 (0.662 to 0.781)
Calibration						
Time range						
Mean calibration	1	1	na	na	O=285; E=269.9	O=285; E=279.0
(O/E)					1.06 (0.94 to 1.19)	1.02 (0.91 to 1.15)
Weak calibration						
- Slope	na	na	na	na	1.05 (0.80 to 1.30)	1.16 (0.93 to 1.40)
Fixed time						
Mean calibration	1	1	na	na	KM=0.49; AvgP=0.51	KM=0.49; AvgP=0.50
(KM / AvgP)					1.04 (0.95 to 1.14) [¶]	1.02 (0.93 to 1.10) [¶]

Weak calibration						
- Slope					1.07 (0.82 to 1.32)	1.20 (0.96 to 1.44)
ICI	na	na	na	na	0.027 (0.012 to 0.070) [¶]	0.021 (0.011 to 0.063) [¶]
E50	na	na	na	na	0.030 (0.007 to 0.072) ¹	0.007 (0.007 to 0.064) [¶]
E90	na	na	na	na	0.061 (0.021 to 0.138) ¹	0.072 (0.022 to 0.123) ¹
Overall						
Brier	0.210 (0.204 to 0.216) ¹	0.209 (0.202 to 0.215) ¹	0.211	0.210	0.224 (0.210 to 0.240) ¹	0.216 (0.202 to 0.232) ¹
scaled Brier	14.3% (11.8% to 16.8%) ¹	14.9% (12.5% to 17.7%) ¹	14.0%	14.5%	10.2% (4.0% to 15.9%) ¹	13.6% (7.1% to 19.1%) [¶]
Clinical usefulness						
Difference in model Net Benefit and treat all Net Benefit at 23% threshold	0.2674-0.2625 = 0.0049	0.2739–0.2625 = 0.0114	-	-	0.3616 - 0.3616 = 0	0.3666-0.3616 = 0.0050

na=not applicable; O=number of observed events over 5 years; E=number of expected events over 5 years; KM=Kaplan-Meier at 5 years; AvgP=average predicted risk at 5 years; ICI=integrated calibration index; E50=; E90=; [¶]The 95% confidence intervals for the overall performance and calibration measures were calculated using non-parametric bootstrap on 500 samples with replacement.

Box 2. Recommendations for assessing performance of prediction models for survival outcomes

Assessment

- For overall performance, we recommend reporting a scaled Brier score for a fixed time point assessment.
- For discrimination, report time-dependent area under the ROC curve at the time point(s) of primary interest. We recommend Uno's weighted approach. For assessment over a time range we recommend either Harrell's C or Uno's C.
- For calibration in an external dataset, while moderate calibration is essential, we recommend following the calibration hierarchy and also reporting mean and weak calibration.

Clinical utility

• If the model is to support clinical decision making, use decision curve analysis to assess the Net Benefit for a range of clinically defendable thresholds.

Publication

- When reporting development of a prediction model, include the baseline survival and ideally a link to a dataset containing the full baseline survival so others can validate the model at a fixed time point or over a range of follow up time. Report model coefficients or the hazard ratios. Both baseline survival and coefficients are essential for independent external validation of the model.
- Use the TRIPOD checklist for reporting prediction model development and validation.



Predicted risk from developed model

Predicted risk from refitted model



